Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

64.47 +0.08 (+0.12%)
Delayed Quote Updated: 1:41 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
23 24 Next >
News headline image
Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue ↗
 
Via Benzinga
News headline image
Exelixis Announces Update on Patent Litigation with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
News headline image
7 Biotech Stocks That Will Make You Rich in 10 Years ↗
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
6 Analysts Have This to Say About Exelixis ↗
 
Via Benzinga
News headline image
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Is Exelixis Stock a Buy Now? ↗
Don't be too quick to dismiss this company as a one-trick pony. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About Exelixis ↗
 
Via Benzinga
News headline image
Four Undervalued Healthcare Stocks for 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. 
Via MarketBeat
News headline image
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —
From Exelixis, Inc.
Via Business Wire
News headline image
2 Top Biotech Stocks to Buy for the Long Haul ↗
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
News headline image
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Where Exelixis Stands With Analysts ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Exelixis ↗
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Exelixis Inks Two Licensing Pacts For Cancer Programs ↗
 
Via Benzinga
News headline image
2 Beaten-Down Growth Stocks to Buy Before the Bull Run ↗
These could become hot buys once investors pivot back to growth stocks. 
Via The Motley Fool
News headline image
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague ↗
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint. 
Via The Motley Fool
News headline image
Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip ↗
These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite. 
Via The Motley Fool
News headline image
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
News headline image
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis (EXEL) Q3 2022 Earnings Call Transcript ↗
EXEL earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
From Exelixis, Inc.
Via Business Wire
News headline image
3 Stocks to Buy Hand Over Fist in December ↗
These stocks could be big winners. 
Via The Motley Fool
News headline image
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
From Exelixis, Inc.
Via Business Wire
News headline image
Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right ↗
Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks. 
Via The Motley Fool
News headline image
The Smartest Stocks to Buy With $20 Right Now ↗
You don't need a mountain of cash to begin building wealth on Wall Street. 
Via The Motley Fool
News headline image
2 No-Brainer Stocks to Buy Right Now for Less than $20 ↗
These stocks are still bargain-priced but benefit from long-term trends. 
Via The Motley Fool
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
News headline image
Here's Why This Growth Stock Is Already My 2022 Winner ↗
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter. 
Via The Motley Fool
News headline image
Looking Into Exelixis's Return On Invested Capital ↗
Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters. 
Via Benzinga
News headline image
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
From Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.